We are live on
!
Find out more
EC
Elmind Capital Portfolio holdings
AUM
$398M
This Fund
S&P 500
This Quarter
Est. Return
+20.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$398M
AUM Growth
+$45.8M
(+13%)
Cap. Flow
+$10.9M
Cap. Flow
% of AUM
2.73%
Top 10 Holdings %
Top 10 Hldgs %
66.6%
Holding
39
New
5
Increased
9
Reduced
6
Closed
4
Avg Time Held
1.7
quarters
Top 10 Avg Time Held
1.3
quarters
Top 20 Avg Time Held
1.5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Legend Biotech
LEGN
|
+$15.4M |
| 2 |
Relay Therapeutics
RLAY
|
+$13.5M |
| 3 |
Summit Therapeutics
SMMT
|
+$8.76M |
| 4 |
Insmed
INSM
|
+$7.87M |
| 5 |
Vaxcyte
PCVX
|
+$7.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$20.6M |
| 2 |
CG Oncology
CGON
|
+$19.7M |
| 3 |
Tyra Biosciences
TYRA
|
+$10.9M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$4.34M |
| 5 |
MBX Biosciences
MBX
|
+$4.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
BioMarin Pharmaceuticals
BMRN
$10.7B
| $2.69M | 0.68% |
47,000
| – | – |
2025 Q4
2 quarters
|
|
27
Immunocore
IMCR
$1.5B
| $2.58M | 0.65% |
81,143
+22,895
| +39% | +$677K |
2025 Q4
2 quarters
|
|
28
Amylyx Pharmaceuticals
AMLX
$3.45B
| $2.01M | 0.51% |
112,000
| – | – |
2025 Q4
2 quarters
|
|
29
Alector
ALEC
$232M
| $1.81M | 0.45% |
900,000
| – | – |
2025 Q4
2 quarters
|
|
30
Septerna Inc
SEPN
$1.75B
| $1.66M | 0.42% |
+49,444
| New | +$1.4M |
2026 Q2
0 quarters
|
|
31
Design Therapeutics
DSGN
$683M
| $1.56M | 0.39% |
107,900
-100,000
| -48% | -$1.25M |
2025 Q4
2 quarters
|
|
32
Sutro Biopharma
STRO
$220M
| $1.06M | 0.27% |
+32,037
| New | +$999K |
2026 Q2
0 quarters
|
|
33
Wave Life Sciences
WVE
$646M
| $1.03M | 0.26% |
177,846
| – | – |
2025 Q4
2 quarters
|
|
|
34
Tyra Biosciences
TYRA
$1.35B
| $639K | 0.16% |
20,000
-330,000
| -94% | -$10.9M |
2025 Q4
2 quarters
|
|
35
enGene Therapeutics
ENGN
$114M
| $363K | 0.09% |
210,000
| – | – |
2025 Q4
2 quarters
|
|
36
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-50,000
| Closed | -$2.01M | – |
|
|
37
CG Oncology
CGON
$5.6B
| – | – |
-291,800
| Closed | -$19.7M | – |
|
38
Edgewise Therapeutics
EWTX
$4.18B
| – | – |
-10,000
| Closed | -$315K | – |
|
|
39
DELISTED
KalVista Pharmaceuticals
KALV
| – | – |
-1,021,300
| Closed | -$20.6M | – |
|
Similar funds
FFS
SFS
SIC
SIAS
HVP
AC
W
CL
Elmind Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Elmind Capital held 39 positions worth $398M, up 13% from $352M the previous quarter. Its ten largest holdings account for 67% of the portfolio.
Elmind Capital's Q2 2026 filing shows 5 new, 9 increased, 6 reduced and 4 closed positions. Its largest new stake was Legend Biotech: 570,569 shares worth $16.5M. The largest sale was KalVista Pharmaceuticals, an estimated $20.6M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- Elmind Capital's largest Q2 2026 buy was Legend Biotech: 570,569 shares worth $16.5M.
- Elmind Capital added most to Relay Therapeutics in Q2 2026, an estimated $13.5M increase.
- Elmind Capital's biggest Q2 2026 reduction was Tyra Biosciences, cutting an estimated $10.9M.
- Elmind Capital fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $20.6M.
- Elmind Capital's ten largest holdings make up 67% of its $398M portfolio in Q2 2026.
- Elmind Capital opened 5 new positions and closed 4 in Q2 2026.
- Elmind Capital's portfolio value rose 13% quarter-over-quarter to $398M.
Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.